First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

MLA

Dawei Xuan, et al. “First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 27, no. 16, Dec. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....06e4848c833b7ebf11a4a1920ed8a1bd&authtype=sso&custid=ns315887.

APA

Dawei Xuan, Valentina Boni, Xiaohua Xin, Shilpa Alekar, Anthony W. Tolcher, Jasgit C. Sachdev, Nehal Lakhani, Victor Moreno, Ruifeng Li, Amy Jackson-Fisher, Erica Stringer-Reasor, Michael L. Maitland, Allison R Moreau, Shivaani Kummar, Michelle Bowers, Emiliano Calvo, Eric L. Powell, & Manish R. Sharma. (2020). First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 27(16).

Chicago

Dawei Xuan, Valentina Boni, Xiaohua Xin, Shilpa Alekar, Anthony W. Tolcher, Jasgit C. Sachdev, Nehal Lakhani, et al. 2020. “First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 27 (16). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....06e4848c833b7ebf11a4a1920ed8a1bd&authtype=sso&custid=ns315887.